Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Summary

This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part. Once the MTD has been defined, the MTD expansion part will be opened for enrollment.

Timeline

Start

2008-11

Primary completion

2011-09

Completion

2012-08

Drugs

Indications